Home›Clinical trials›A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

Recruiting now. Registry record last updated August 21, 2026.

Who can join
Adults 18+, have osteoarthritis (joint pain), BMI 27+.
What you take
orforglipron, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 2.7 years; your own time in it is usually shorter.
What you get
Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 3Sponsor Eli Lilly and CompanyDrug orforglipronClass GLP-1 RASites 26 USEnrollment target 800

What this study is for

Primary condition: Osteoarthritis.

Full scientific study title: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have osteoarthritis (joint pain), BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
  • Have tried at least once to lose weight through diet but were unsuccessful
  • Have osteoarthritis of the knee and at least one of the following conditions:
  • Be over 50 years old
  • Have morning knee stiffness that lasts about 30 minutes

Key exclusion criteria

  • Have gained or lost more than 11 pounds within 90 days prior to screening
  • Have had a surgery for obesity or plan to have one in the next 18 months
  • Have an active knee infection
  • Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure

Where this trial is enrolling

This trial has 26 sites across 17 states. Contact a site coordinator directly to start screening.

Arizona2 sites
  • Arizona Research Center
    Phoenix, Arizona
    602-863-6363
  • AMR Clinical
    Tempe, Arizona
    602-910-3343
California2 sites
  • Care Access - Huntington Beach
    Huntington Beach, California
    714-378-2440
  • Care Access - Thousand Oaks
    Thousand Oaks, California
    805-778-5143
Colorado1 site
  • Legacy Clinical Trials
    Colorado Springs, Colorado
    719-387-7572
Connecticut1 site
  • Chase Medical Research, LLC
    Waterbury, Connecticut
    203-419-4420
Georgia2 sites
  • Care Access - Decatur
    Decatur, Georgia
    678-470-4394
  • North Georgia Clinical Research
    Woodstock, Georgia
    678-494-5735
Illinois1 site
  • Northwestern University
    Chicago, Illinois
    312-503-2315
Kansas1 site
  • AMR Clinical
    Newton, Kansas
    316-804-7304
Massachusetts1 site
  • MedVadis Research Corporation
    Waltham, Massachusetts
    617-744-1310
Missouri2 sites
  • StudyMetrix Research
    City of Saint Peters, Missouri
    636-387-5100
  • AMR Clinical
    Kansas City, Missouri
New Jersey1 site
  • Cardio Metabolic Institute
    Somerset, New Jersey
    732-846-7000 x 108
North Carolina1 site
  • Carolina Research Center
    Shelby, North Carolina
    704-600-6052
Pennsylvania1 site
  • University Orthopedics Center
    Altoona, Pennsylvania
South Dakota1 site
  • Care Access - Rapid City
    Rapid City, South Dakota
    877-791-0656
Tennessee1 site
  • AMR Clinical
    Knoxville, Tennessee
    865-305-9100
Texas5 sites
  • Mercy Family Clinic
    Dallas, Texas
    281-944-3610
  • Juno Research
    Houston, Texas
    713-779-5494
  • Biopharma Informatic, LLC
    Houston, Texas
    281-944-3610
  • Activian Clinical Research
    Kingwood, Texas
    832-969-3401
  • Advanced Rheumatology of Houston - Woodlands
    The Woodlands, Texas
    936-681-4882
Virginia2 sites
  • Charlottesville Medical Research
    Charlottesville, Virginia
    434-817-2442
  • Gershon Pain Specialists
    Virginia Beach, Virginia
    757-496-2050
Washington1 site
  • Northwest Clinical Research Center
    Bellevue, Washington

Timeline

Started enrolling: September 15, 2025. Expected completion: May 2028. Last updated on ClinicalTrials.gov: August 21, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.